Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning - Report of two pediatric cases

J. G. Dolgin, D. E. Nix, David E. Nix, W. A. Watson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Activated charcoal is commonly used to inhibit the absorption of phenytoin after acute overdose. There are also reports of multiple-dose activated charcoal (MDAC) increasing the clearance of phenytoin in adults. We describe our experience modeling phenytoin pharmacokinetics during therapy with MDAC in the treatment of two cases of acute phenytoin poisoning in children. After extensive attempts at modeling the serum phenytoin concentrations, simulations were performed to identify the possible consequences of MDAC administration. Phenytoin elimination was more rapid than was expected, based on previously reported phenytoin pharmacokinetic parameters. Moreover, the time to peak phenytoin concentration and time course of phenytoin intoxication appeared to be shorter than available reports of phenytoin intoxication treated with a single dose of activated charcoal. MDAC may prevent continued phenytoin absorption and increase phenytoin elimination rate via gastrointestinal dialysis. The effect of MDAC on the clearance of phenytoin can be described by a first-order elimination rate constant of approximately 0.02-0.04/h.

Original languageEnglish (US)
Pages (from-to)646-649
Number of pages4
JournalDICP, Annals of Pharmacotherapy
Volume25
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Charcoal
Phenytoin
Poisoning
Pharmacokinetics
Pediatrics
Dialysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning - Report of two pediatric cases. / Dolgin, J. G.; Nix, D. E.; Nix, David E.; Watson, W. A.

In: DICP, Annals of Pharmacotherapy, Vol. 25, No. 6, 1991, p. 646-649.

Research output: Contribution to journalArticle

@article{b40117861738496f998a360d3d8eaf04,
title = "Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning - Report of two pediatric cases",
abstract = "Activated charcoal is commonly used to inhibit the absorption of phenytoin after acute overdose. There are also reports of multiple-dose activated charcoal (MDAC) increasing the clearance of phenytoin in adults. We describe our experience modeling phenytoin pharmacokinetics during therapy with MDAC in the treatment of two cases of acute phenytoin poisoning in children. After extensive attempts at modeling the serum phenytoin concentrations, simulations were performed to identify the possible consequences of MDAC administration. Phenytoin elimination was more rapid than was expected, based on previously reported phenytoin pharmacokinetic parameters. Moreover, the time to peak phenytoin concentration and time course of phenytoin intoxication appeared to be shorter than available reports of phenytoin intoxication treated with a single dose of activated charcoal. MDAC may prevent continued phenytoin absorption and increase phenytoin elimination rate via gastrointestinal dialysis. The effect of MDAC on the clearance of phenytoin can be described by a first-order elimination rate constant of approximately 0.02-0.04/h.",
author = "Dolgin, {J. G.} and Nix, {D. E.} and Nix, {David E.} and Watson, {W. A.}",
year = "1991",
language = "English (US)",
volume = "25",
pages = "646--649",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetic simulation of the effect of multiple-dose activated charcoal in phenytoin poisoning - Report of two pediatric cases

AU - Dolgin, J. G.

AU - Nix, D. E.

AU - Nix, David E.

AU - Watson, W. A.

PY - 1991

Y1 - 1991

N2 - Activated charcoal is commonly used to inhibit the absorption of phenytoin after acute overdose. There are also reports of multiple-dose activated charcoal (MDAC) increasing the clearance of phenytoin in adults. We describe our experience modeling phenytoin pharmacokinetics during therapy with MDAC in the treatment of two cases of acute phenytoin poisoning in children. After extensive attempts at modeling the serum phenytoin concentrations, simulations were performed to identify the possible consequences of MDAC administration. Phenytoin elimination was more rapid than was expected, based on previously reported phenytoin pharmacokinetic parameters. Moreover, the time to peak phenytoin concentration and time course of phenytoin intoxication appeared to be shorter than available reports of phenytoin intoxication treated with a single dose of activated charcoal. MDAC may prevent continued phenytoin absorption and increase phenytoin elimination rate via gastrointestinal dialysis. The effect of MDAC on the clearance of phenytoin can be described by a first-order elimination rate constant of approximately 0.02-0.04/h.

AB - Activated charcoal is commonly used to inhibit the absorption of phenytoin after acute overdose. There are also reports of multiple-dose activated charcoal (MDAC) increasing the clearance of phenytoin in adults. We describe our experience modeling phenytoin pharmacokinetics during therapy with MDAC in the treatment of two cases of acute phenytoin poisoning in children. After extensive attempts at modeling the serum phenytoin concentrations, simulations were performed to identify the possible consequences of MDAC administration. Phenytoin elimination was more rapid than was expected, based on previously reported phenytoin pharmacokinetic parameters. Moreover, the time to peak phenytoin concentration and time course of phenytoin intoxication appeared to be shorter than available reports of phenytoin intoxication treated with a single dose of activated charcoal. MDAC may prevent continued phenytoin absorption and increase phenytoin elimination rate via gastrointestinal dialysis. The effect of MDAC on the clearance of phenytoin can be described by a first-order elimination rate constant of approximately 0.02-0.04/h.

UR - http://www.scopus.com/inward/record.url?scp=0025772425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025772425&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 646

EP - 649

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 6

ER -